| [1] |
Smith V，Osianlis T，Vollenhoven B.Prevention of ovarian hyperstimulation syndrome：A review[J].Obstet Gynecol Int，2015，2015（1）：514 159.
|
| [2] |
Practice Committee of the American Society for Reproductive Medicine.Prevention and treatment of moderate and severe ovarian hyperstimu-lation syndrome：a guideline[J].Fertil Steril，2016，106（7）：1634-1647.
|
| [18] |
王培，凌秀凤，李秀玲，等.促性腺激素释放激素拮抗剂在防治卵巢过度刺激综合征中的应用[J].中华临床医师杂志（电子版），2013，7（19）：8584-8587.
|
| [3] |
Wang YQ，Yu N，Xu WM，et al.Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome：A controlled clinical study[J].Exp Ther Med，2014，8（6）：1855-1860.
|
| [4] |
Golan A，Weissman A.Symposium：Update on prediction and management of OHSS A modern classification of OHSS[J].Reprod Biomed Online，2009，19（1）：28-32.
|
| [5] |
Eftekhar M，Miraj S，Mortazavifar Z.The effect of luteal phase gonadotropin-releasing hormone antagonist admini stration on IVF outcomes in women at risk of OHSS[J].Int J Reprod Biomed（Yazd），2016，14（8）：507-510.
|
| [6] |
Humaidan P，Quartarolo J，Papanikolaou EG.Preventing ovarian hyperstimulation syndrome：guidance for the clinician[J].Fertil Steril，2010，94（2）：389-400.
|
| [7] |
Swanton A，Storey L，McVeigh E，et al.IVF outcome in women with PCOS，PCO and normal ovarian morphology[J].Eur J Obstet Gynecol Reprod Biol，2010，149（1）：68-71.[8]Palumbo A，Avila J，Naftolin F.The ovarian renin-angiotensin system （OVRAS）：a major factor in ovarian function and disease[J].Reprod Sci，2016，23（12）：1644-1655.
|
| [9] |
Wang L，Li H，Ai J，et al.Possible involvement of single nucleotide polymorphisms in anti-Müllerian hormone signaling pathway in the pathogenesis of early OHSS in Han Chinese women[J].Int J Clin Exp Pathol，2015，8（8）：9552-9559.
|
| [10] |
Minaretzis D，Jakubowski M，Mortola JF，et al.Gonadotropinreleasing hormone receptor gene expression in human ovary and granulosa-lutein cells[J].J Clin Endocrinol Metab，1995，80（2）：430-434.
|
| [11] |
Herr D，Sallmann A，Bekes I，et al.VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5[J].Gynecol Oncol，2012，127（1）：210-216.
|
| [12] |
Peitsidis P，Agrawal R.Role of vascular endothelial growth factor in women with PCO and PCOS：a systematic review[J].Reprod Biomed Online，2010，20（4）：444-452.
|
| [13] |
Abramov Y，Barak V，Nisman B，et al.Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome[J].Fertil Steril，1997，67（2）：261-265.
|
| [14] |
Guerrero HE，Stein P，Asch RH，et al.Effect of a gonadotropinreleasing hormone agonist on luteinizing hormone receptors and steroidogenesis in ovarian cells[J].Fertil Steril，1993，59（4）：803-808.
|
| [15] |
Asimakopoulos B，Nikolettos N，Nehls B，et al.Gonadotropinreleasing hormone antagonists do not influence the secretion of steroid horm ones but affect the secretion of vascular endothelial growth factor from human granulose luteinized cell cultures[J].Fertil Steril，2006，86（3）：636-641.
|
| [16] |
Lainas GT，Kolibianakis EM，Sfontouris IA，et al.Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome[J].BJOG，2014，121（7）：848-855.
|
| [17] |
Hill MJ，Chason RJ，Payson MD，et al.GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes[J].Reprod Biomed Online，2012，25（3）：284-291.
|
| [19] |
Ko HS，Kim N，Park YG.Re：Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist admi nistration in women with severe early ovarian hyperstimulation syndrome[J].BJOG，2015，122（4）：585.
|
| [20] |
Nastri CO，Teixeira DM，Moroni RM，et al.Ovarian hyperstimulation syndrom e：pathophysiology，staging，prediction and prevention[J].Ultrasound Obstet Gynecol，2015，45（4）：377-393.
|
